Palo Alto, United States
Avenue Biosciences, headquartered in San Francisco with roots in Helsinki, is pioneering advancements in biotechnology and pharmaceuticals. Founded in 2023, the company aims to dismantle production barriers in protein biologics, thereby ensuring that crucial therapies are accessible. Their innovation lies in a unique protein engineering platform that merges organic biology with machine learning to enhance protein production, a concept deeply rooted in scientific research from the University of Helsinki.
The company recently secured a $5.70M seed investment on 01 January 2026, supported by notable investors such as Inventure, Tesi, Voima Ventures, the University of Helsinki, Balnord, and Dimerent. This funding is intended to push their mission of transforming protein biologics with groundbreaking engineering techniques, ultimately streamlining production, improving quality, and expanding therapeutic avenues.
